Skip to main content
Erschienen in: Pathology & Oncology Research 1/2008

01.03.2008 | Original Paper

Matrix Metalloproteinase-9 Expression in the Normal Mucosa–Adenoma–Dysplasia–Adenocarcinoma Sequence of the Colon

verfasst von: László Herszényi, Ferenc Sipos, Orsolya Galamb, Norbert Solymosi, István Hritz, Pál Miheller, Lajos Berczi, Béla Molnár, Zsolt Tulassay

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

It has been proposed that matrix metalloproteinases (MMPs) play a role in tumor invasion. We determined protein expression of matrix metalloproteinase-9 (MMP-9) in colorectal cancer (CRC), corresponding normal mucosa and colorectal adenomas. For confirmation of immunohistochemical results MMP-9 TaqMan RT-PCR analysis was performed. Expression of MMP-9 was determined on paraffin embedded biopsy sections by immunohistochemistry in 31 CRC patients (from cancer tissue and corresponding normal mucosa) and in 30 patients with adenoma (nine adenomas with high grade of dysplasia). MMP-9 immunostaining was determined semi-quantitatively. For Taqman RT-PCR analyses normal mucosa (n = 5), adenoma without (n = 6) and with high grade dysplasia (n = 7) and CRC (n = 10) were investigated. Statistical analysis with ANOVA, LSD test and correlation analysis were performed. P value of <0.05 was considered significant. The MMP-9 expression in CRC was significantly higher compared to adenomas or the normal mucosa (P = 0.001). Significantly higher expression of MMP-9 has been observed in adenomas with high grade dysplasia compared to other adenomas or normal colon (P < 0.001). Diffuse strong MMP-9 expression was present in tumor as well as in stromal cells. In adenoma samples, dysplastic epithelial cells showed moderate intensive cytoplasmic MMP-9 expression, with a clear-cut differentiation between dysplastic and non-dysplastic areas. Staining intensity correlated with the grade of CRC. We demonstrate a significantly higher expression of MMP-9 in adenoma with high grade dysplasia—CRC sequence as compared to normal tissue. The over-expression of MMP-9 strongly suggests its association with colorectal carcinogenesis.
Literatur
1.
Zurück zum Zitat Berger AC, Sigurdson ER, LeVoyer T, et al (2005) Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 23:8706–8712PubMedCrossRef Berger AC, Sigurdson ER, LeVoyer T, et al (2005) Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 23:8706–8712PubMedCrossRef
2.
Zurück zum Zitat Liang H, Wang XN, Wang BG, et al (2006) Prognostic factors of young patients with colon cancer after surgery. World J Gastroenterol 12:1458–1462PubMed Liang H, Wang XN, Wang BG, et al (2006) Prognostic factors of young patients with colon cancer after surgery. World J Gastroenterol 12:1458–1462PubMed
3.
Zurück zum Zitat Fuszek P, Horváth HC, Speer G, et al (2006) Location and age at onset of colorectal cancer in Hungarian patients between 1993 and 2004. The high number of advanced cases supports the need for a colorectal cancer screening program in Hungary. Anticancer Res 26:531–537 Fuszek P, Horváth HC, Speer G, et al (2006) Location and age at onset of colorectal cancer in Hungarian patients between 1993 and 2004. The high number of advanced cases supports the need for a colorectal cancer screening program in Hungary. Anticancer Res 26:531–537
4.
Zurück zum Zitat Liotta LA, Stetler-Stevenson WG (1991) Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51:S5054–S5059 Liotta LA, Stetler-Stevenson WG (1991) Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51:S5054–S5059
5.
Zurück zum Zitat Dano K, Behrendt N, Hoyer-Hansen G, et al (2005) Plasminogen activations and cancer. Thromb Haemost 93:676–681PubMed Dano K, Behrendt N, Hoyer-Hansen G, et al (2005) Plasminogen activations and cancer. Thromb Haemost 93:676–681PubMed
6.
Zurück zum Zitat Herszényi L, Plebani M, Carraro P, et al (1997) Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. Am J Gastroenterol 92:843–847PubMed Herszényi L, Plebani M, Carraro P, et al (1997) Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. Am J Gastroenterol 92:843–847PubMed
7.
Zurück zum Zitat Plebani M, Herszényi L, Cardin R, et al (1995) Cysteine and serine proteases in gastric cancer. Cancer 76:367–375PubMedCrossRef Plebani M, Herszényi L, Cardin R, et al (1995) Cysteine and serine proteases in gastric cancer. Cancer 76:367–375PubMedCrossRef
8.
Zurück zum Zitat Plebani M, Herszényi L, Carraro P, et al (1997) Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin Exp Metastasis 15:418–425PubMedCrossRef Plebani M, Herszényi L, Carraro P, et al (1997) Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin Exp Metastasis 15:418–425PubMedCrossRef
9.
Zurück zum Zitat Herszényi L, Plebani M, Carraro P, et al (1999) The role of cysteine and serine proteases in colorectal cancer. Cancer 86:1135–1142PubMedCrossRef Herszényi L, Plebani M, Carraro P, et al (1999) The role of cysteine and serine proteases in colorectal cancer. Cancer 86:1135–1142PubMedCrossRef
10.
Zurück zum Zitat Farinati F, Herszényi L, Plebani M, et al (1996) Increased levels of cathepsin B and L, urokinase-type plasminogen activator and inhibitor type-1 as an early event in gastric carcinogenesis. Carcinogenesis 17:2581–2587PubMedCrossRef Farinati F, Herszényi L, Plebani M, et al (1996) Increased levels of cathepsin B and L, urokinase-type plasminogen activator and inhibitor type-1 as an early event in gastric carcinogenesis. Carcinogenesis 17:2581–2587PubMedCrossRef
11.
Zurück zum Zitat Johnson LL, Dyer R, Hupe DJ (1998) Matrix metalloproteinases. Curr Opin Chem Biol 2:466–471PubMedCrossRef Johnson LL, Dyer R, Hupe DJ (1998) Matrix metalloproteinases. Curr Opin Chem Biol 2:466–471PubMedCrossRef
12.
Zurück zum Zitat Stamenkovic I (2003) Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200:448–464PubMedCrossRef Stamenkovic I (2003) Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200:448–464PubMedCrossRef
13.
Zurück zum Zitat Mysliwiec AG, Ornstein DL (2002) Matrix metalloproteinases in colorectal cancer. Clin Colorectal Cancer 1:208–219PubMedCrossRef Mysliwiec AG, Ornstein DL (2002) Matrix metalloproteinases in colorectal cancer. Clin Colorectal Cancer 1:208–219PubMedCrossRef
14.
Zurück zum Zitat Sato H, Okada Y, Seiki M (1997) Membrane-type metalloproteinases (MT-MMPs) in cell invasion. Thromb Haemost 78:497–500PubMed Sato H, Okada Y, Seiki M (1997) Membrane-type metalloproteinases (MT-MMPs) in cell invasion. Thromb Haemost 78:497–500PubMed
15.
Zurück zum Zitat Nelson AR, Fingleton B, Rothenberg ML, et al (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMed Nelson AR, Fingleton B, Rothenberg ML, et al (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMed
16.
Zurück zum Zitat Sier CF, Kubben FJ, Ganesh S, et al (1996) Tissue levels of matrix metalloproteinase MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinomas. Br J Cancer 74:413–417PubMed Sier CF, Kubben FJ, Ganesh S, et al (1996) Tissue levels of matrix metalloproteinase MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinomas. Br J Cancer 74:413–417PubMed
17.
Zurück zum Zitat Matsuyama Y, Takao S, Aikou T (2002) Comparison of matrix metalloproteinases expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 80:105–110PubMedCrossRef Matsuyama Y, Takao S, Aikou T (2002) Comparison of matrix metalloproteinases expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 80:105–110PubMedCrossRef
18.
Zurück zum Zitat Herszényi L, Hritz I, Pregun I, et al (2007) Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in the esophageal carcinogenesis. World J Gastroenterol 13:676–682PubMed Herszényi L, Hritz I, Pregun I, et al (2007) Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in the esophageal carcinogenesis. World J Gastroenterol 13:676–682PubMed
19.
Zurück zum Zitat Saito K, Takeha S, Shiba K, et al (2000) Clinicopathologic significance of urokinase receptor- and MMP-9 positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogeneous metastasis. Int J Cancer 86:24–29PubMedCrossRef Saito K, Takeha S, Shiba K, et al (2000) Clinicopathologic significance of urokinase receptor- and MMP-9 positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogeneous metastasis. Int J Cancer 86:24–29PubMedCrossRef
20.
Zurück zum Zitat Collins HM, Morris TM, Watson SA (2001) Spectrum of matrix metalloproteinase expression in primary metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane-type-1-matrix metalloproteinase. Br J Cancer 84:1664–1670PubMedCrossRef Collins HM, Morris TM, Watson SA (2001) Spectrum of matrix metalloproteinase expression in primary metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane-type-1-matrix metalloproteinase. Br J Cancer 84:1664–1670PubMedCrossRef
21.
Zurück zum Zitat Roeb E, Dietrich CG, Winograd R, et al (2001) Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma: differential activity of matrix metalloproteinase-9. Cancer 92:2680–2691PubMedCrossRef Roeb E, Dietrich CG, Winograd R, et al (2001) Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma: differential activity of matrix metalloproteinase-9. Cancer 92:2680–2691PubMedCrossRef
22.
Zurück zum Zitat Waas ET, Lomme RM, deGroot J, et al (2002) Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 86:1876–1883PubMedCrossRef Waas ET, Lomme RM, deGroot J, et al (2002) Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 86:1876–1883PubMedCrossRef
23.
Zurück zum Zitat Murray D, Morrin M, McDonnel S (2004) Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res 24:489–494PubMed Murray D, Morrin M, McDonnel S (2004) Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res 24:489–494PubMed
25.
Zurück zum Zitat Thiéfin G, Dupont A, Guillou PJ, et al (2007) Beneficial influence of microsatellite instability on gelatinase-tissue inhibitors of metalloproteinase balance in colorectal cancer. Anticancer Res 27:583–588PubMed Thiéfin G, Dupont A, Guillou PJ, et al (2007) Beneficial influence of microsatellite instability on gelatinase-tissue inhibitors of metalloproteinase balance in colorectal cancer. Anticancer Res 27:583–588PubMed
26.
Zurück zum Zitat Sardinha TC, Nogueras JJ, Xiong H, et al (2000) Membrane-type 1 matrix metalloproteinase mRNA expression in colorectal cancer. Dis Colon Rectum 43:389–395PubMedCrossRef Sardinha TC, Nogueras JJ, Xiong H, et al (2000) Membrane-type 1 matrix metalloproteinase mRNA expression in colorectal cancer. Dis Colon Rectum 43:389–395PubMedCrossRef
27.
Zurück zum Zitat Papadopoulou S, Scorilas A, Arnogianaki N, et al (2001) Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumour Biol 22:383–389PubMedCrossRef Papadopoulou S, Scorilas A, Arnogianaki N, et al (2001) Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumour Biol 22:383–389PubMedCrossRef
28.
Zurück zum Zitat Leeman MF, McKay JA, Murray GI (2002) Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 55:758–762PubMedCrossRef Leeman MF, McKay JA, Murray GI (2002) Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 55:758–762PubMedCrossRef
29.
Zurück zum Zitat Pesta M, Holubec L, Topolcan O, et al (2005) Quantitative estimation of matrix metalloproteinase 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 25:3387–3391PubMed Pesta M, Holubec L, Topolcan O, et al (2005) Quantitative estimation of matrix metalloproteinase 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 25:3387–3391PubMed
30.
Zurück zum Zitat Zeng ZS, Huang Y, Cohen AM, et al (1996) Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 14:3133–3140PubMed Zeng ZS, Huang Y, Cohen AM, et al (1996) Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 14:3133–3140PubMed
31.
Zurück zum Zitat Baker EA, Bergin FG, Leaper DJ (2000) Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 87:1215–1221PubMedCrossRef Baker EA, Bergin FG, Leaper DJ (2000) Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 87:1215–1221PubMedCrossRef
32.
Zurück zum Zitat Curran S, Dundas SR, Buxton J, et al (2004) Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Cancer Res 10:8229–8234CrossRef Curran S, Dundas SR, Buxton J, et al (2004) Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Cancer Res 10:8229–8234CrossRef
33.
Zurück zum Zitat Illemann M, Bird N, Majeed A, et al (2006) MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 4:293–302PubMedCrossRef Illemann M, Bird N, Majeed A, et al (2006) MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 4:293–302PubMedCrossRef
34.
Zurück zum Zitat Kirman I, Jain S, Cekic V, et al (2006) Altered plasma matrix metalloproteinase-9/tissue inhibitor of matrix (corrected) metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer. Surg Endosc 20:482–486PubMedCrossRef Kirman I, Jain S, Cekic V, et al (2006) Altered plasma matrix metalloproteinase-9/tissue inhibitor of matrix (corrected) metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer. Surg Endosc 20:482–486PubMedCrossRef
35.
Zurück zum Zitat Islekel H, Oktay G, Terzi C, et al (2007) Matrix metalloproteinase-9, -3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem Funct 25:433–441PubMedCrossRef Islekel H, Oktay G, Terzi C, et al (2007) Matrix metalloproteinase-9, -3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem Funct 25:433–441PubMedCrossRef
36.
Zurück zum Zitat Dukes CE (1932) The classification of cancer of the rectum. J Pathol 35:323–332CrossRef Dukes CE (1932) The classification of cancer of the rectum. J Pathol 35:323–332CrossRef
37.
Zurück zum Zitat Turnbull RB, Kyle K, Watson FR, et al (1967) Cancer of the colon: the influence of the no-touch isolation on the survival rates. Ann Surg 166:420–427PubMedCrossRef Turnbull RB, Kyle K, Watson FR, et al (1967) Cancer of the colon: the influence of the no-touch isolation on the survival rates. Ann Surg 166:420–427PubMedCrossRef
38.
Zurück zum Zitat Sipos F, Galamb O, Herszényi L, et al (2007) Elevated insulin-like growth factor 1 receptor, hepatocyte growth factor receptor and telomerase expression in mild ulcerative colitis. Scand J Gastroenterol 23:1–10 Sipos F, Galamb O, Herszényi L, et al (2007) Elevated insulin-like growth factor 1 receptor, hepatocyte growth factor receptor and telomerase expression in mild ulcerative colitis. Scand J Gastroenterol 23:1–10
39.
Zurück zum Zitat Bernhard EJ, Gruber SB, Muschel RJ (1994) Direct evidence linking expression of matrix metalloproteinase 9 (92kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 91:4293–4297PubMedCrossRef Bernhard EJ, Gruber SB, Muschel RJ (1994) Direct evidence linking expression of matrix metalloproteinase 9 (92kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 91:4293–4297PubMedCrossRef
40.
Zurück zum Zitat Legrand C, Gilles C, Zahm JM, et al (1999) Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodelling. J Cell Biol 146:517–529PubMedCrossRef Legrand C, Gilles C, Zahm JM, et al (1999) Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodelling. J Cell Biol 146:517–529PubMedCrossRef
41.
Zurück zum Zitat Tang Y, Nakada MT, Kesavan P, et al (2005) Extracellular matrix metalloproteinase inducer stimulates tumor angioegenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65:3193–3199PubMed Tang Y, Nakada MT, Kesavan P, et al (2005) Extracellular matrix metalloproteinase inducer stimulates tumor angioegenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65:3193–3199PubMed
42.
Zurück zum Zitat Mook OR, Frederiks WM, Van Noorden CJF (2004) The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705:69–89PubMed Mook OR, Frederiks WM, Van Noorden CJF (2004) The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705:69–89PubMed
43.
Zurück zum Zitat Zeng ZS, Guillem JG (1996) Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal stromal cells. Br J Cancer 74:1161–1167PubMed Zeng ZS, Guillem JG (1996) Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal stromal cells. Br J Cancer 74:1161–1167PubMed
44.
Zurück zum Zitat Lubbe WJ, Zhou ZY, Fu W, et al (2006) Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. Clin Cancer Res 12:1876–1882PubMedCrossRef Lubbe WJ, Zhou ZY, Fu W, et al (2006) Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. Clin Cancer Res 12:1876–1882PubMedCrossRef
45.
Zurück zum Zitat Gao Q, Meijer MJ, Kubben FJ, et al (2005) Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 37:584–592PubMedCrossRef Gao Q, Meijer MJ, Kubben FJ, et al (2005) Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 37:584–592PubMedCrossRef
46.
Zurück zum Zitat McKaig BC, McWilliams D, Watson SA, et al (2003) Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 162:1355–1360PubMed McKaig BC, McWilliams D, Watson SA, et al (2003) Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 162:1355–1360PubMed
47.
Zurück zum Zitat Nosho K, Yoshida M, Yamamoto H, et al (2005) Association of Ets-related transcriptional E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 26:892–899PubMedCrossRef Nosho K, Yoshida M, Yamamoto H, et al (2005) Association of Ets-related transcriptional E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 26:892–899PubMedCrossRef
48.
Zurück zum Zitat Rath T, Roderfeld M, Graf J, et al (2006) Enhanced expression of MMP-7 and MMP 13 in inflammatory bowel disease: a precancerous potential? Inflamm Bowel Dis 12:1025–1035PubMedCrossRef Rath T, Roderfeld M, Graf J, et al (2006) Enhanced expression of MMP-7 and MMP 13 in inflammatory bowel disease: a precancerous potential? Inflamm Bowel Dis 12:1025–1035PubMedCrossRef
49.
Zurück zum Zitat Harada K, Hiraoka S, Kato J, et al (2007) Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features. Br J Cancer 97:1425–1431PubMedCrossRef Harada K, Hiraoka S, Kato J, et al (2007) Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features. Br J Cancer 97:1425–1431PubMedCrossRef
50.
Zurück zum Zitat Hashimoto K, Shimizu Y, Suehiro Y, et al (2008) Hypermethylation status of APC inversely correlates with the presence of submucosal invasion in laterally spreading colorectal tumors. Mol Carcinog 47:1–8PubMedCrossRef Hashimoto K, Shimizu Y, Suehiro Y, et al (2008) Hypermethylation status of APC inversely correlates with the presence of submucosal invasion in laterally spreading colorectal tumors. Mol Carcinog 47:1–8PubMedCrossRef
51.
Zurück zum Zitat Model F, Osborn N, Ahlquist D, et al (2007) Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. Mol Cancer Res 5:153–163PubMedCrossRef Model F, Osborn N, Ahlquist D, et al (2007) Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. Mol Cancer Res 5:153–163PubMedCrossRef
52.
Zurück zum Zitat Holten-Andersen MN, Christensen IJ, Nielsen HJ, et al (2002) Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 8:156–164PubMed Holten-Andersen MN, Christensen IJ, Nielsen HJ, et al (2002) Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 8:156–164PubMed
53.
Zurück zum Zitat Pesta M, Topolcan O, Holubec L Jr, et al (2007) Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res 27:1863–1867PubMed Pesta M, Topolcan O, Holubec L Jr, et al (2007) Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res 27:1863–1867PubMed
54.
Zurück zum Zitat Frederiksen C, Lykke J, Christensen IJ, et al (2007) Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer. Scand J Clin Lab Invest 67:545–552PubMedCrossRef Frederiksen C, Lykke J, Christensen IJ, et al (2007) Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer. Scand J Clin Lab Invest 67:545–552PubMedCrossRef
55.
Zurück zum Zitat Ogata Y, Matono K, Sasatomi T, et al (2005) The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother Pharmacol 57:577–583PubMedCrossRef Ogata Y, Matono K, Sasatomi T, et al (2005) The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother Pharmacol 57:577–583PubMedCrossRef
56.
Zurück zum Zitat Sorensen NM, Byström P, Christensen IJ, et al (2007) TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 13:4117–4122PubMedCrossRef Sorensen NM, Byström P, Christensen IJ, et al (2007) TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 13:4117–4122PubMedCrossRef
57.
Zurück zum Zitat Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer-Trials and tribulations. Science 295:2387–2392PubMedCrossRef Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer-Trials and tribulations. Science 295:2387–2392PubMedCrossRef
58.
Zurück zum Zitat Vihinen P, Ala-Aho R, Kahari VM (2005) Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5:203–220PubMedCrossRef Vihinen P, Ala-Aho R, Kahari VM (2005) Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5:203–220PubMedCrossRef
59.
Zurück zum Zitat Burg-Roderfeld M, Roderfeld M, Wagner S, et al (2007) MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells. Int J Oncol 30:985–992PubMed Burg-Roderfeld M, Roderfeld M, Wagner S, et al (2007) MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells. Int J Oncol 30:985–992PubMed
60.
Zurück zum Zitat Pavlaki M, Zucker S (2003) Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 22:177–203PubMedCrossRef Pavlaki M, Zucker S (2003) Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 22:177–203PubMedCrossRef
61.
Zurück zum Zitat van Smarle S, van Vliet A, Sollie F, et al (2005) Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Pharmacol Ther 43:282–293 van Smarle S, van Vliet A, Sollie F, et al (2005) Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Pharmacol Ther 43:282–293
62.
Zurück zum Zitat Chiappori AA, Eckhardt SG, Bukowski R, et al (2007) A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res 13:2091–2099PubMedCrossRef Chiappori AA, Eckhardt SG, Bukowski R, et al (2007) A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res 13:2091–2099PubMedCrossRef
Metadaten
Titel
Matrix Metalloproteinase-9 Expression in the Normal Mucosa–Adenoma–Dysplasia–Adenocarcinoma Sequence of the Colon
verfasst von
László Herszényi
Ferenc Sipos
Orsolya Galamb
Norbert Solymosi
István Hritz
Pál Miheller
Lajos Berczi
Béla Molnár
Zsolt Tulassay
Publikationsdatum
01.03.2008
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 1/2008
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9004-5

Weitere Artikel der Ausgabe 1/2008

Pathology & Oncology Research 1/2008 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.